Top Suppliers:I want be here
Related CAS#:
21416-67-1 21416-87-5
33497-71-1 24584-09-6
2138147-44-9 2088284-98-2
2089650-33-7 1352442-86-4
154052-16-1 2135331-64-3
2228353-00-0 1270350-35-0
2135336-84-2 10537-09-4

21416-67-1

21416-67-1 structure
21416-67-1 structure
  • Name: Razoxane
  • Chemical Name: 4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
  • CAS Number: 21416-67-1
  • Molecular Formula: C11H16N4O4
  • Molecular Weight: 268.26900
  • Catalog: Biochemical Inhibitor Immune inhibitor
  • Create Date: 2018-06-20 18:11:28
  • Modify Date: 2025-08-25 19:12:20
  • Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].
Name 4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
Synonyms 4,4'-propylenebis(piperazine-2,6-dione)
4,4'-Propane-1,2-diyldipiperazine-2,6-dione
4,4'-(1-Methylethylene)bis(2,6-piperazinedione)
dl-1,2-bis(3,5-dioxopiperazin-1-yl)-propane
Propyliminum
RAZOXANUM
1,2-bis(3,5-dioxopiperazin-1-yl)-propane
(+)-1,2-bis(3,5-dioxopiperazinyl)propane
(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane
Razoxane
Description Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].
Related Catalog
Target

Topoisomerase II

In Vitro Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.
In Vivo Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2]. Animal Model: Sprague-Dawley rats[2] Dosage: 30 mg/kg or 10 mg/kg per day Administration: Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation Result: Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
References

[1]. J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704.

[2]. F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5(1):9-16.
Density 1.333g/cm3
Boiling Point 531.5ºC at 760mmHg
Melting Point 193ºC
Molecular Formula C11H16N4O4
Molecular Weight 268.26900
Flash Point 275.3ºC
Exact Mass 268.11700
PSA 98.82000
Vapour Pressure 1.33E-13mmHg at 25°C
Index of Refraction 1.534
Storage condition room temp
Water Solubility DMSO: soluble40mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TL6389900
CHEMICAL NAME :
2,6-Piperazinedione, 4,4'-propylenedi-
CAS REGISTRY NUMBER :
21416-67-1
BEILSTEIN REFERENCE NO. :
0821182
LAST UPDATED :
199612
DATA ITEMS CITED :
15
MOLECULAR FORMULA :
C11-H16-N4-O4
MOLECULAR WEIGHT :
268.31
WISWESSER LINE NOTATION :
T6VMV ENTJ EY1&1- ET6VMV ENTJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
3650 mg/kg/2Y-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - hematuria Blood - aplastic anemia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
600 mg/kg/34W-I
TOXIC EFFECTS :
Blood - leukopenia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
6467 mg/kg/6Y-I
TOXIC EFFECTS :
Blood - normocytic anemia Blood - thrombocytopenia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
500 mg/kg
TOXIC EFFECTS :
Tumorigenic - active as anti-cancer agent
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
693 mg/kg/77W-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
4650 mg/kg/2Y-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
2693 mg/kg/3Y-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Skin and Appendages - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
3650 mg/kg/2Y-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
TYPE OF TEST :
Micronucleus test

MUTATION DATA

TEST SYSTEM :
Rodent - hamster
DOSE/DURATION :
100 mg/kg
REFERENCE :
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 52,725,1985
RIDADR NONH for all modes of transport
RTECS TL6389900
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:21416-67-1 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 21416-67-1 | Chemsrc address: https://www.chemsrc.com/en/baike/964185.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved